GlassScriptPhysician profile
Leslie M Hutton
NPI 1003186362
$10,030.00
in general payments reported to CMS, 2019-2025
37 companies · $1,398 in 2025
The $1,398 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,085 · 2022: $2,159 · 2023: $2,312 · 2024: $2,076 · 2025: $1,398.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,786.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,785.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,023.46 | 2021-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $1,241.39 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $1,017.41 | 2021-2025 | |
| Novo Nordisk INC | $847.34 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $838.12 | 2021-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Pfizer INC. | $573.20 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $489.32 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $426.28 | 2021-2025 | Jardiance, Synjardy, Tradjenta |
| Bayer Healthcare Pharmaceuticals INC. | $419.70 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $358.92 | 2022-2025 | |
| Esperion Therapeutics, INC. | $199.05 | 2021-2025 | Nexletol |
| Exact Sciences Corporation | $180.59 | 2023-2024 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $140.76 | 2021-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $134.92 | 2021-2022 | |
| Astellas Pharma US INC | $103.08 | 2021 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leslie Hutton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.